-
Founded in:
2000-01-03 -
Country:
China -
Address:
No. 65, Huaihe East Road, Xucheng Town, Xuyi County -
Tax NO.:
91320830703838125N -
Registered Funds:
30 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Salvia Root P.E Tanshinone IIA 20% |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Capillary Wormwood Herb Extract |
Has liver protection, immune enhancement and antiviral effects
More
Has liver protection, immune enhancement and antiviral effects |
0 | ||
| Gardenia jasminoides, ext. |
Has liver protection, immune enhancement and antiviral effects
More
Has liver protection, immune enhancement and antiviral effects |
92457-01-7 | 0 | |
| Scutellaria baicalensis, ext. |
Has liver protection, immune enhancement and antiviral effects
More
Has liver protection, immune enhancement and antiviral effects |
94279-99-9 | 0 | |
| Honeysuckle extract (calculated as chlorogenic acid) |
Has liver protection, immune enhancement and antiviral effects
More
Has liver protection, immune enhancement and antiviral effects |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Capillary Wormwood Herb Extract |
Has liver-protective, immune-enhancing and antiviral effects
More
Has liver-protective, immune-enhancing and antiviral effects |
0 | ||
| Gardenia jasminoides, ext. |
Has liver-protective, immune-enhancing and antiviral effects
More
Has liver-protective, immune-enhancing and antiviral effects |
92457-01-7 | 0 | |
| Scutellaria baicalensis, ext. |
Has liver-protective, immune-enhancing and antiviral effects
More
Has liver-protective, immune-enhancing and antiviral effects |
94279-99-9 | 0 | |
| Honeysuckle extract (calculated as chlorogenic acid) |
Has liver-protective, immune-enhancing and antiviral effects
More
Has liver-protective, immune-enhancing and antiviral effects |
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Ozagrel sodium |
This product is a thromboxane (TX) synthase inhibitor, which can inhibit the generation of thromboxane A2 (TXA2) from prostaglandin H2 (PGH2), and promote the transfer of PGH2 derived from platelets to endothelial cells. Endothelial cells are used to synthesize PGI2, thereby improving the abnormal balance between TXA2 and prostaglandin PGI2. Theoretically, it can inhibit platelet aggregation and vasodilation. This product can improve movement disorders in the acute stage of cerebral thrombosis, improve circulatory disorders in the acute stage of cerebral ischemia, and improve abnormal energy metabolism during cerebral ischemia. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels, increase the ratio of 6-Keto-PGF1a/TXB2, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by middle cerebral artery occlusion in rats. The half-maximal inhibitory concentration IC50 of this product for human platelet aggregation is low, at 4nM. Experiments using autologous blood injected into the subarachnoid hemorrhage model showed that continuous intravenous injection of this product has the effects of inhibiting blood TXB2 concentration and cerebral vasoconstriction.
More
This product is a thromboxane (TX) synthase inhibitor, which can inhibit the generation of thromboxane A2 (TXA2) from prostaglandin H2 (PGH2), and promote the transfer of PGH2 derived from platelets to endothelial cells. Endothelial cells are used to synthesize PGI2, thereby improving the abnormal balance between TXA2 and prostaglandin PGI2. Theoretically, it can inhibit platelet aggregation and vasodilation. This product can improve movement disorders in the acute stage of cerebral thrombosis, improve circulatory disorders in the acute stage of cerebral ischemia, and improve abnormal energy metabolism during cerebral ischemia. Animal experiments have shown that intravenous administration can reduce plasma TXB2 levels, increase the ratio of 6-Keto-PGF1a/TXB2, inhibit platelet aggregation caused by different inducers, and prevent cerebral infarction caused by middle cerebral artery occlusion in rats. The half-maximal inhibitory concentration IC50 of this product for human platelet aggregation is low, at 4nM. Experiments using autologous blood injected into the subarachnoid hemorrhage model showed that continuous intravenous injection of this product has the effects of inhibiting blood TXB2 concentration and cerebral vasoconstriction. |
189224-26-8 | 10 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Neostigmine Methyl Sulfate |
It exerts a complete cholinergic effect by inhibiting the activity of cholinesterase, directly stimulating the nicotinic receptors (N2 receptors) on the motor end plates of skeletal muscles. It has a weaker effect on glandular, eye, cardiovascular and bronchial smooth muscles, promotes gastric contraction and increases gastric acid secretion, promotes peristalsis of the small and large intestines, especially the colon, prevents intestinal relaxation and promotes the downward movement of intestinal contents. It has a stronger excitatory effect on skeletal muscles but a weaker effect on the central nervous system.
More
It exerts a complete cholinergic effect by inhibiting the activity of cholinesterase, directly stimulating the nicotinic receptors (N2 receptors) on the motor end plates of skeletal muscles. It has a weaker effect on glandular, eye, cardiovascular and bronchial smooth muscles, promotes gastric contraction and increases gastric acid secretion, promotes peristalsis of the small and large intestines, especially the colon, prevents intestinal relaxation and promotes the downward movement of intestinal contents. It has a stronger excitatory effect on skeletal muscles but a weaker effect on the central nervous system. |
51-60-5 | 31 |